Dorr

Soligenix, formerly known as DOR BioPharma, is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases and address public health threats. The company operates through two primary segments: BioTherapeutics, which targets unmet medical needs in oncology and inflammation, and Public Health Solutions, which focuses on biodefense countermeasures and vaccines. Its lead clinical candidates include HyBryte for cutaneous T-cell lymphoma and SGX301 for the treatment of inflammatory conditions. Soligenix is also recognized for its work in developing heat-stable vaccines against ricin toxin and emerging viral threats like Ebola and Marburg.